Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
Stock
ARGX
ARGX News & Events
-
Add to Watchlist
Trade ARGX
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Stock Price Prediction
Technical
Valuation
Financials
Earnings
Should I Buy
News & Events
ARGX News
Analysis of IBB ETF Trading Dynamics
1d ago
NASDAQ.COM
Dianthus Therapeutics Early Decision Boosts Stock Surge
3d ago
stocktwits
VYVGART Shows Promise as Targeted Treatment for Ocular Myasthenia Gravis
6d ago
Newsfilter
argenx SE Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
6d ago
Yahoo Finance
Significant Milestones in Biotech Sector This Week
Feb 27 2026
NASDAQ.COM
Argenx Reports Strong Q4 Results and Positive Phase 3 Study Outcomes
Feb 27 2026
Benzinga
Argenx Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
Feb 26 2026
Benzinga
Argenx Reports Positive Phase 3 Results for Vyvgart in Eye Disease
Feb 26 2026
Newsfilter
Show More News
ARGX Events
No data
ARGX Monitor News
argenx SE Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
Mar 12 2026
argenx SE Reports Strong Q4 Results Amid Market Weakness
Mar 05 2026
argenx Reports Strong Q4 Earnings and Future Growth Plans
Feb 26 2026
argenx SE reaches 20-day high amid market gains
Jan 27 2026
argenx SE transitions leadership amid market strength
Jan 05 2026
argenx discontinues Phase 3 TED studies, shares decline
Dec 15 2025
ARGX Earnings Analysis
Argenx SE Earnings: Immunology Innovations Drive Growth- Intellectia AI™
4 months ago
argenx SE 2024: Earnings Growth & Strategic Advancements- Intellectia AI™
1 years ago
People Also Watch
